Monitor whether the company achieves full capital raise given the best-efforts nature of the offering and recent Nasdaq compliance challenges. Track clinical trial progress of ART27.13 and ART26.12, and watch for any updates on Nasdaq listing status by the March 30, 2026 compliance deadline. The bridge notes' conversion terms could lead to significant dilution if triggered.
Executive Summary
Artelo Biosciences is a clinical-stage biopharmaceutical company developing therapeutics targeting lipid-signaling pathways, including the endocannabinoid system. The company is conducting a best-efforts IPO to raise approximately $10.8 million in net proceeds, primarily for working capital and general corporate purposes. Key clinical programs include ART27.13 for cancer-related anorexia and ART26.12 for chemotherapy-induced peripheral neuropathy, with promising early trial data. The company faces significant risks including Nasdaq delisting due to low stockholders' equity, reliance on bridge financing, and substantial dilution for new investors.
Key Financial Metrics
Key Facts
- Clinical-stage biopharmaceutical company focused on lipid-signaling modulation pathways and the endocannabinoid system
- Offering 1,641,587 shares of common stock at an assumed price of $7.31 per share, with estimated net proceeds of $10.8 million
- Best efforts offering with no minimum amount required, increasing risk that full capital raise may not be achieved
- ART27.13 showed 6.38% mean weight gain vs. 5.42% loss in placebo in cancer anorexia trial; ART26.12 showed favorable safety in Phase 1
- Company received Nasdaq delisting notice due to stockholders' equity below $2.5 million, with compliance deadline of March 30, 2026
- Completed a 1-for-3 reverse stock split on March 10, 2026, reducing outstanding shares from 2.1 million to approximately 736,127
- Recently issued $350,300 in bridge notes with 12% interest, convertible upon default at $0.125 or 75% of lowest trading price
- As of December 31, 2025, company had $600,000 in cash and a stockholders' deficit of $1.272 million
Financial Impact
Approximately $10.8 million in net proceeds if full offering is sold, which would increase cash from $600,000 to $11.4 million and eliminate the stockholders' deficit
Risk Factors
- Risk of Nasdaq delisting if stockholders' equity does not meet $2.5 million requirement by March 30, 2026
- Best efforts offering with no minimum raise could result in insufficient capital for business plans
- Substantial dilution for new investors - $4.07 per share based on $7.31 offering price vs. $3.24 as-adjusted book value
- Reliance on bridge financing with potentially dilutive conversion terms if default occurs
- Clinical trial failures could significantly impact valuation given the company's early stage
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001640334-26-000515 |
| Document: 0001640334-26-000515-index-headers.html | 0001640334-26-000515 |
| Document: 0001640334-26-000515-index.html | 0001640334-26-000515 |
| Document: 0001640334-26-000515.txt | 0001640334-26-000515 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 8-K | $3.11 | awaiting T+60 | — | $2.22 (+28.62%) |
Sep 16, 2026 5w ago | Press Release | $3.75 | awaiting T+60 | — | $2.22 (−40.80%) |
Aug 13, 2026 10w ago | Press Release | $6.83 | awaiting T+60 | — | $2.22 (−67.50%) |
Jul 16, 2026 14w ago | DEFA14A | $1.14 $0.3622 | ▼ −68.23% | ▼ −71.94% | $2.22 (+94.74%) |
Jul 16, 2026 14w ago | Press Release | $1.14 $0.3622 | ▼ −68.23% | ▼ −71.94% | $2.22 (+94.74%) |
Jul 13, 2026 15w ago | Press Release | $1.05 $0.3844 | ▼ −63.39% | ▼ −67.38% | $2.22 (+111.43%) |
Jul 2, 2026 16w ago | DEFA14A | $1.11 $0.4522 | ▲ +59.26% | ▲ +60.98% | $2.22 (−100.00%) |
May 27, 2026 21w ago | 8-K | $1.46 $0.6920 | ▲ +52.60% | ▲ +54.34% | $2.22 (−52.05%) |
May 18, 2026 23w ago | 424B5 | $1.36 $0.7587 | ▼ −44.21% | ▼ −50.50% | $2.22 (+63.24%) |
May 15, 2026 23w ago | 8-K | $1.46 $0.7330 | ▼ −49.79% | ▼ −54.65% | $2.22 (+52.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers